Skip to content

Study on antibody levels after COVID-19 vaccination

Study on antibody levels after COVID-19 vaccination

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051264
Enrollment
Unknown
Registered
2021-09-17
Start date
2021-09-22
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

case series:Nil

Sponsors

Luzhou Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1.People aged over 3 years; 2.Complete two doses of inactivated COVID-19 vaccine and produce the vaccine from the same manufacturer; 3.People who voluntarily accept antibody testing and sign informed consent; 4.Patients with hypertension who are in good health and well controlled by drugs; 5.Patients with diabetes who are in good health and well controlled by drugs.

Exclusion criteria

Exclusion criteria: 1.Pregnant women; 2.Previous infection with novel coronavirus; 3.Any other contraindications to inactivated COVID-19 vaccine vaccination.

Design outcomes

Primary

MeasureTime frame
SARS-cov-2 neutralizing antibody;

Secondary

MeasureTime frame
IgG;IgM;

Countries

China

Contacts

Public ContactLei Zhi

Luzhou Center for Disease Control and Prevention

676111501@qq.com+86 830 2523770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026